Evidence map›Paper›PMID 42182341›Full record

ArticlebioRxiv : the preprint server for biology2026

H2AX C-Terminal Dipeptide Truncation: A Master Switch of the DNA Damage Response.

Faith M Joseph, Matthew V Holt, John M Jerome, Linda Zhang, Ashley G Boice, Patricia D Castro, Sofía I Aramburu, Ruhee Dere, Susan M Rosenberg, David R Rowley and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Faith M JosephTranslational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX.
Matthew V HoltVerna & Marrs McLean Department of Biochemistry & Molecular Pharmacology, Baylor College of Medicine, Houston, TX.
John M JeromeDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Linda ZhangTranslational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX.
Ashley G BoiceCenter for Precision and Environmental Health, Baylor College of Medicine, Houston, TX.
Patricia D CastroDepartment of Pathology & Immunology, Baylor College of Medicine, Houston, TX.
Sofía I AramburuDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX.
Ruhee DereCenter for Precision and Environmental Health, Baylor College of Medicine, Houston, TX.
Susan M RosenbergVerna & Marrs McLean Department of Biochemistry & Molecular Pharmacology, Baylor College of Medicine, Houston, TX.ORCID 0000-0003-1444-473X
David R RowleyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.
Nicolas L YoungVerna & Marrs McLean Department of Biochemistry & Molecular Pharmacology, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-3323-2815

Funding

TMEM106b as a lysosomal adaptor to influence brain aging and tau pathogenesisP01AG066606 · NIA · BAYLOR COLLEGE OF MEDICINE · PI JANKOWSKY, JOANNA L · 2021 to 2025
$13.5M
Harnessing Proteins as Drugs: the Protectome of Cancer- and Aging-Prevention ProteinsDP1AG072751 · NIA · BAYLOR COLLEGE OF MEDICINE · PI ROSENBERG, SUSAN M · 2020 to 2024
$5.6M
METABOLIC REGULATION IN LEUKEMIA-INITIATING CELLSR01CA193235 · NCI · BAYLOR COLLEGE OF MEDICINE · PI NAKADA, DAISUKE · 2015 to 2024
$4.6M
Mechanisms of Endogenous DNA Damage PromotionR01CA250905 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MILLER, KYLE M, ROSENBERG, SUSAN M · 2020 to 2024
$3.3M
Neutron encoded activity based probesR01GM139295 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI YOUNG, DAMIAN WINSTON, YOUNG, NICOLAS L · 2020 to 2024
$2.2M
Chromatin dysregulation in neurodevelopmental disordersR01NS136375 · NINDS · DUKE UNIVERSITY · PI Anne Elizabeth West · 2024 to 2026
$1.7M
Developmental control of chromatin states in cancerR01CA276663 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ian J Davis · 2023 to 2026
$1.7M
Lysosomal NADPH metabolism regulates proteostasis, aging and tauopathyR01AG074540 · NIA · BAYLOR COLLEGE OF MEDICINE · PI DANG, WEIWEI · 2024 to 2025
$1.0M
NCI NIH HHS R01 CA193235NCI NIH HHS R01 CA250905NCI NIH HHS R01 CA276663NIA NIH HHS DP1 AG072751NIA NIH HHS P01 AG066606NIA NIH HHS R01 AG074540NIGMS NIH HHS R01 GM139295NINDS NIH HHS R01 NS136375
6 · The paper itself

Abstract

Phosphorylation of histone H2AX at serine 139 (γH2AX) by ATM/ATR kinases is a central marker of the DNA damage response (DDR), widely used to detect DNA double-strand breaks. However, the molecular basis for tissue- and context-specific variation in γH2AX signaling remains poorly defined. Here we discover a post-translational truncation of H2AX, catalyzed by lysine demethylase 4A (KDM4A), which removes two C-terminal amino acids critical for ATM/ATR-dependent phosphorylation. This truncation renders H2AX refractory to γH2AX formation, effectively bypassing canonical DDR signaling. Truncated H2AX accumulates in select cell lines, primary cells, solid tumors, and normal tissues. Genetic knockdown or pharmacologic inhibition of KDM4A reduces H2AX truncation, restores γH2AX induction, and enhances DNA repair capacity. Conversely, KDM4A overexpression promotes H2AX truncation, impairs γH2AX signaling, and exacerbates DNA damage accumulation. This previously unrecognized regulatory axis implicates KDM4A catalyzed H2AX truncation as a superseding mechanism that represses the canonical DDR and disrupts the correlation between γH2AX and DNA damage. This dioxygenase-based protease mechanism represents a new class of proteases and is the first example of c-terminal dipeptide protein truncation. This discovery has broad implications in the basic science of genome maintenance, wound healing, cancer, combinatorial therapy, precision medicine, and technologies such as gene editing.

Identifiers

PMID42182341
PMCPMC13192945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.